Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366152> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4313366152 endingPage "182.45" @default.
- W4313366152 startingPage "182.45" @default.
- W4313366152 abstract "Abstract Multiple Sclerosis (MS) is a neuro-degenerative autoimmune disease, progressive in nature, that lacks biomarkers for diagnosis or progression. We described a population of CD4+ T cells that express the CD40 receptor, Th40 cells, which proved causal in murine models of autoimmunity. Hypothesis Peripheral blood Th40 numbers reflect MS progression and their control correlates with improvement. Peripheral blood and cerebral spinal fluid from MS patients and disease controls were examined for HLA haplotype and PBMC were characterized by flow cytometry. Random sampling of CIS, RRMS, SPMS and PPMS patients demonstrated diverse HLA haplotypes; DR2 / DQ6 were highly represented but surprisingly DR4, DR3 and DQ2 were prominent. In antigen recall, each HLA haplotype preferred unique myelin-based antigens when presenting to Th40 cells. Percentages of Th40 cells in peripheral blood of CIS and RRMS had a wide range while the range in PPMS and SPMS was tight yet significantly elevated. CSF from RRMS patients had Th40 cell percentages mirroring peripheral blood. RRMS subjects had elevated B cells that surprisingly were the major source of IL-17. Rituximab treated subjects demonstrated a significant but temporal reduction in Th40 cell numbers; FoxP3+ cells were elevated while Th40 inflammatory-cytokine production was reduced. Conclusions The wide range of Th40 cell numbers in CIS and RRMS but universally high numbers in SPMS suggest that Th40 cell number expansions in MS reflect progression. Th40 cells in CSF demonstrate access to the CNS and an important correlation between peripheral blood and CNS. Antigen recall to myelin demonstrates Th40 pathogenicity. Rituximab treatment ablates B cells that then affect pathogenic effector Th40 cells." @default.
- W4313366152 created "2023-01-06" @default.
- W4313366152 creator A5004534805 @default.
- W4313366152 creator A5057863189 @default.
- W4313366152 creator A5059851485 @default.
- W4313366152 date "2019-05-01" @default.
- W4313366152 modified "2023-09-26" @default.
- W4313366152 title "Peripheral Blood Th40 cells Reflect Disease Progression and Are Controlled by Rituximab in Human Multiple Sclerosis" @default.
- W4313366152 doi "https://doi.org/10.4049/jimmunol.202.supp.182.45" @default.
- W4313366152 hasPublicationYear "2019" @default.
- W4313366152 type Work @default.
- W4313366152 citedByCount "1" @default.
- W4313366152 countsByYear W43133661522021 @default.
- W4313366152 crossrefType "journal-article" @default.
- W4313366152 hasAuthorship W4313366152A5004534805 @default.
- W4313366152 hasAuthorship W4313366152A5057863189 @default.
- W4313366152 hasAuthorship W4313366152A5059851485 @default.
- W4313366152 hasConcept C137061746 @default.
- W4313366152 hasConcept C147483822 @default.
- W4313366152 hasConcept C188280979 @default.
- W4313366152 hasConcept C202751555 @default.
- W4313366152 hasConcept C203014093 @default.
- W4313366152 hasConcept C2776090121 @default.
- W4313366152 hasConcept C2779338263 @default.
- W4313366152 hasConcept C2780640218 @default.
- W4313366152 hasConcept C2780653079 @default.
- W4313366152 hasConcept C2908647359 @default.
- W4313366152 hasConcept C55493867 @default.
- W4313366152 hasConcept C71924100 @default.
- W4313366152 hasConcept C86803240 @default.
- W4313366152 hasConcept C8891405 @default.
- W4313366152 hasConcept C99454951 @default.
- W4313366152 hasConceptScore W4313366152C137061746 @default.
- W4313366152 hasConceptScore W4313366152C147483822 @default.
- W4313366152 hasConceptScore W4313366152C188280979 @default.
- W4313366152 hasConceptScore W4313366152C202751555 @default.
- W4313366152 hasConceptScore W4313366152C203014093 @default.
- W4313366152 hasConceptScore W4313366152C2776090121 @default.
- W4313366152 hasConceptScore W4313366152C2779338263 @default.
- W4313366152 hasConceptScore W4313366152C2780640218 @default.
- W4313366152 hasConceptScore W4313366152C2780653079 @default.
- W4313366152 hasConceptScore W4313366152C2908647359 @default.
- W4313366152 hasConceptScore W4313366152C55493867 @default.
- W4313366152 hasConceptScore W4313366152C71924100 @default.
- W4313366152 hasConceptScore W4313366152C86803240 @default.
- W4313366152 hasConceptScore W4313366152C8891405 @default.
- W4313366152 hasConceptScore W4313366152C99454951 @default.
- W4313366152 hasIssue "1_Supplement" @default.
- W4313366152 hasLocation W43133661521 @default.
- W4313366152 hasOpenAccess W4313366152 @default.
- W4313366152 hasPrimaryLocation W43133661521 @default.
- W4313366152 hasRelatedWork W1599996543 @default.
- W4313366152 hasRelatedWork W1972597838 @default.
- W4313366152 hasRelatedWork W2008949385 @default.
- W4313366152 hasRelatedWork W2012012488 @default.
- W4313366152 hasRelatedWork W2016209669 @default.
- W4313366152 hasRelatedWork W201680594 @default.
- W4313366152 hasRelatedWork W2019101100 @default.
- W4313366152 hasRelatedWork W2043505088 @default.
- W4313366152 hasRelatedWork W2069039175 @default.
- W4313366152 hasRelatedWork W2413888000 @default.
- W4313366152 hasVolume "202" @default.
- W4313366152 isParatext "false" @default.
- W4313366152 isRetracted "false" @default.
- W4313366152 workType "article" @default.